Area of research
Pulmonary and Respiratory Medicine · Physiology
Research interest
Research interests include Asthma and respiratory diseases, Lung Cancer Treatments and Mutations, Pleural and Pulmonary Diseases, and Lung Cancer Research Studies.
Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and <i>MET</i> -amplification ( <i>MET</i> amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma.
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
29P Real-world safety of osimertinib in Chinese patients with non-small cell lung cancer (NSCLC)
Candida albicans elicits protective allergic responses via platelet mediated T helper 2 and T helper 17 cell polarization
Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19
Inhibition of macrophage migration inhibitory factor (MIF) as a therapeutic target in bleomycin-induced pulmonary fibrosis rats
Withdrawn: Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy
Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Activation of M1 macrophages plays a critical role in the initiation of acute lung injury
<scp>ILC</scp>2 frequency and activity are inhibited by glucocorticoid treatment via <scp>STAT</scp> pathway in patients with asthma
Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway
A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes